Protocols

Arix IPO raises £100M for new biotech investments; Santhera sets up shop in Massachusetts

• As expected, the UK’s Arix Biosciences has raised £100 million in its IPO, which will now fuel a new round of investments in biotech companies. “We have a highly experienced international team and this new capital enables us to continue our commitment to supporting businesses in the vanguard of medical innovation, with the ultimate goal of improving outcomes for patients and unlocking value for investors,” said CEO Joe Anderson.

• Switzerland’s Santhera has opened up shop in Massachusetts. The new facility, reports the Boston Business Journal, will start off with a staff of about 20 under the guidance of Tom Bazemore.

• Takeda and TiGenix NV {$TIG) announced new Phase III data from their ADMIRE-CD clinical trial, which “indicated that investigational compound Cx601, a suspension of allogeneic expanded adipose-derived stem cells (eASC), maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.”


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Endpoints News Webinar

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->